...
ptct-img

PTC Therapeutics Inc, Common Stock

PTCT

NSQ

$45.486

-$0.07

(-0.15%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.51B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
120.34K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.63
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$23.58 L
$54.16 H
$45.486

About PTC Therapeutics Inc, Common Stock

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePTCTSectorS&P500
1-Week Return-6.27%-0.4%-1.9%
1-Month Return5.98%-4.57%-0.37%
3-Month Return23.97%-10.14%4.19%
6-Month Return27.37%-5.67%9.34%
1-Year Return59.92%2.53%25.19%
3-Year Return8.84%-0.39%26.48%
5-Year Return-7.64%34.57%85.39%
10-Year Return-10.49%103.62%187.16%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue306.98M380.77M538.59M698.80M937.82M[{"date":"2019-12-31","value":32.73,"profit":true},{"date":"2020-12-31","value":40.6,"profit":true},{"date":"2021-12-31","value":57.43,"profit":true},{"date":"2022-12-31","value":74.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue12.13M18.94M32.33M44.68M65.49M[{"date":"2019-12-31","value":18.53,"profit":true},{"date":"2020-12-31","value":28.93,"profit":true},{"date":"2021-12-31","value":49.37,"profit":true},{"date":"2022-12-31","value":68.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit294.85M361.82M506.26M654.12M872.34M[{"date":"2019-12-31","value":33.8,"profit":true},{"date":"2020-12-31","value":41.48,"profit":true},{"date":"2021-12-31","value":58.04,"profit":true},{"date":"2022-12-31","value":74.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin96.05%95.03%94.00%93.61%93.02%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.94,"profit":true},{"date":"2021-12-31","value":97.87,"profit":true},{"date":"2022-12-31","value":97.46,"profit":true},{"date":"2023-12-31","value":96.85,"profit":true}]
Operating Expenses487.64M759.70M881.21M1.09B1.31B[{"date":"2019-12-31","value":37.17,"profit":true},{"date":"2020-12-31","value":57.91,"profit":true},{"date":"2021-12-31","value":67.17,"profit":true},{"date":"2022-12-31","value":83.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(192.80M)(397.88M)(374.94M)(439.93M)(349.40M)[{"date":"2019-12-31","value":-19279800000,"profit":false},{"date":"2020-12-31","value":-39787500000,"profit":false},{"date":"2021-12-31","value":-37494300000,"profit":false},{"date":"2022-12-31","value":-43992500000,"profit":false},{"date":"2023-12-31","value":-34940200000,"profit":false}]
Total Non-Operating Income/Expense(59.62M)(115.71M)(229.42M)(238.43M)(456.11M)[{"date":"2019-12-31","value":-5961900000,"profit":false},{"date":"2020-12-31","value":-11570900000,"profit":false},{"date":"2021-12-31","value":-22941900000,"profit":false},{"date":"2022-12-31","value":-23843300000,"profit":false},{"date":"2023-12-31","value":-45611300000,"profit":false}]
Pre-Tax Income(239.93M)(402.93M)(518.34M)(587.49M)(696.11M)[{"date":"2019-12-31","value":-23992600000,"profit":false},{"date":"2020-12-31","value":-40293200000,"profit":false},{"date":"2021-12-31","value":-51834000000,"profit":false},{"date":"2022-12-31","value":-58748700000,"profit":false},{"date":"2023-12-31","value":-69611000000,"profit":false}]
Income Taxes11.65M35.23M5.56M(28.47M)(69.51M)[{"date":"2019-12-31","value":33.07,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":15.79,"profit":true},{"date":"2022-12-31","value":-80.82,"profit":false},{"date":"2023-12-31","value":-197.3,"profit":false}]
Income After Taxes(251.58M)(438.16M)(523.90M)(559.02M)(626.60M)[{"date":"2019-12-31","value":-25157600000,"profit":false},{"date":"2020-12-31","value":-43816000000,"profit":false},{"date":"2021-12-31","value":-52390100000,"profit":false},{"date":"2022-12-31","value":-55901700000,"profit":false},{"date":"2023-12-31","value":-62660400000,"profit":false}]
Income From Continuous Operations(251.58M)(438.16M)(523.90M)(559.02M)(641.70M)[{"date":"2019-12-31","value":-25157600000,"profit":false},{"date":"2020-12-31","value":-43816000000,"profit":false},{"date":"2021-12-31","value":-52390100000,"profit":false},{"date":"2022-12-31","value":-55901700000,"profit":false},{"date":"2023-12-31","value":-64170100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(251.58M)(438.16M)(523.90M)(559.02M)(626.60M)[{"date":"2019-12-31","value":-25157600000,"profit":false},{"date":"2020-12-31","value":-43816000000,"profit":false},{"date":"2021-12-31","value":-52390100000,"profit":false},{"date":"2022-12-31","value":-55901700000,"profit":false},{"date":"2023-12-31","value":-62660400000,"profit":false}]
EPS (Diluted)(4.47)(6.54)(7.43)(7.33)(6.54)[{"date":"2019-12-31","value":-447,"profit":false},{"date":"2020-12-31","value":-654,"profit":false},{"date":"2021-12-31","value":-743,"profit":false},{"date":"2022-12-31","value":-733,"profit":false},{"date":"2023-12-31","value":-654,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PTCT
Cash Ratio 1.66
Current Ratio 2.10
Quick Ratio 2.04

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PTCT
ROA (LTM) -5.15%
ROE (LTM) -7740.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PTCT
Debt Ratio Lower is generally better. Negative is bad. 1.57
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.57

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PTCT
Trailing PE NM
Forward PE 18.05
P/S (TTM) 3.90
P/B 1743.27
Price/FCF NM
EV/R 3.28
EV/Ebitda NM
PEG 0.81

FAQs

What is PTC Therapeutics Inc share price today?

PTC Therapeutics Inc (PTCT) share price today is $45.486

Can Indians buy PTC Therapeutics Inc shares?

Yes, Indians can buy shares of PTC Therapeutics Inc (PTCT) on Vested. To buy PTC Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PTCT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of PTC Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of PTC Therapeutics Inc (PTCT) via the Vested app. You can start investing in PTC Therapeutics Inc (PTCT) with a minimum investment of $1.

How to invest in PTC Therapeutics Inc shares from India?

You can invest in shares of PTC Therapeutics Inc (PTCT) via Vested in three simple steps:

  • Click on Sign Up or Invest in PTCT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in PTC Therapeutics Inc shares
What is PTC Therapeutics Inc 52-week high and low stock price?

The 52-week high price of PTC Therapeutics Inc (PTCT) is $54.16. The 52-week low price of PTC Therapeutics Inc (PTCT) is $23.58.

What is PTC Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of PTC Therapeutics Inc (PTCT) is

What is PTC Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of PTC Therapeutics Inc (PTCT) is 1743.27

What is PTC Therapeutics Inc dividend yield?

The dividend yield of PTC Therapeutics Inc (PTCT) is 0.00%

What is the Market Cap of PTC Therapeutics Inc?

The market capitalization of PTC Therapeutics Inc (PTCT) is $3.51B

What is PTC Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of PTC Therapeutics Inc is PTCT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top